

### EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.
2. Authorization for this examiner's amendment was given in a telephone interview with Ms. Heidi Struse on December 17, 2009.
3. The application has been amended as follows:
  - A. At claim 7 (currently amended), page 6, last two lines, the compound has been amended to read as follows:  
  
--4-(3-fluorophenyl)-6-methoxy-N, N, 2-trimethyl-1-oxo-1, 2-dihydroisoquinoline-3-carboxamide,--.
  - B. Claims 8, 12-18, and 22 have been canceled.
  - C. Claim 9 has been amended to read as follows:  
  
--9. (Currently amended) A method of treating a condition in a mammal, the treatment of which is effected or facilitated by K<sub>v</sub>1.5 inhibition, which comprises administering a compound of Claim 7 in an amount that is effective at inhibiting K<sub>v</sub>1.5 wherein the condition is cardiac arrhythmia.--
  - D. At claim 21, line 2, the phrase "a compound of claim 1" has been amended to read as -- a compound of claim 7--.
  - E. At claim 23, lines 2 and 3, the phrase "a compound of claim 1" has been amended to read as -- a compound of claim 7--.

### REASONS FOR ALLOWANCE

The following is an examiner's statement of reasons for allowance:

4. Based upon the response filed September 3, 2009, the rejection under 35 U.S.C. 102(b) based upon Takeda Chemical Industries, LTD. is withdrawn.
5. Applicants preserve the right to file divisional applications drawn to the non-elected subject matter.
6. Claims 7, 21, and 23 has been amended to improve the clarity.
7. Non-elected claims 8-11 and 23 are rejoined with the invention of Group I.
8. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."
9. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zinna N. Davis whose telephone number is 571-272-0682.
10. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

[SIGNATURE BLOCK ON THE NEXT PAGE]

Art Unit: 1625

/Zinna Northington Davis/  
**Zinna Northington Davis**  
**Primary Examiner**  
**Group 1600-AU 1625**

Znd  
12.18.2009